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Abstract

Author Manuscript

Cellular redox balance plays a significant role in the regulation of hematopoietic stem-progenitor
cell (HSC/MPP) self-renewal and differentiation. Unregulated changes in cellular redox
homeostasis are associated with the onset of most hematological disorders. However, accurate
measurement of the redox state in stem cells is difficult because of the scarcity of HSC/MPPs.
Glutathione (GSH) constitutes the most abundant pool of cellular antioxidants. Thus, GSH
metabolism may play a critical role in hematological disease onset and progression. A major
limitation to studying GSH metabolism in HSC/MPPs has been the inability to measure
quantitatively GSH concentrations in small numbers of HSC/MPPs. Current methods used to
measure GSH levels not only rely on large numbers of cells, but also rely on the chemical/
structural modification or enzymatic recycling of GSH and therefore are likely to measure only
total glutathione content accurately. Here, we describe the validation of a sensitive method used
for the direct and simultaneous quantitation of both oxidized and reduced GSH via liquid
chromatography followed by tandem mass spectrometry (LC-MS/MS) in HSC/MPPs isolated
from bone marrow. The lower limit of quantitation (LLOQ) was determined to be 5.0 ng/mL for
GSH and 1.0 ng/mL for GSSG with lower limits of detection at 0.5 ng/mL for both glutathione
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species. Standard addition analysis utilizing mouse bone marrow shows that this method is both
sensitive and accurate with reproducible analyte recovery. This method combines a simple
extraction with a platform for the high-throughput analysis, allows for efficient determination of
GSH/GSSG concentrations within the HSC/MPP populations in mouse, chemotherapeutic
treatment conditions within cell culture, and human normal/leukemia patient samples. The data
implicate the importance of the modulation of GSH/GSSG redox couple in stem cells related
diseases.

Graphical abstract
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Glutathione, γ-L-glutamyl-L-cysteinylglycine, (GSH) is an endogenous tripeptide involved
in many cellular processes including apoptosis, cellular detoxification, and redox
signaling[1, 2]. Currently, GSH is thought of as a major cellular reducing agent, with high
intracellular concentrations reported to range from 0.5–10 mM, that aids in protection from
ROS mediated injury [3–5]. GSH/GSSG homeostasis is tightly regulated with depletion or
oxidation of the cellular GSH pool leading to the activation of anti-oxidant signaling
pathways, gene transcription, and GSH synthesis accomplished via glutamate-cysteine ligase
(GCL) activity. Oxidizing cellular conditions lead to the heterodimerization of the GCL
subunits, GCLC (GCL catalytic subunit) and GCLM (GCL modifier subunit) [6, 7] which,
results in increased GCL activity. GSH activity is subsequently regulated via cycling the
cysteinyl thiol (pKa= 9.2) through oxidized and reduced states. GSH-mediated cellular
detoxification may be accomplished by the direct conjugation of GSH, to xenobiotics and
other endogenously produced small molecules via glutathione-S-transferase (GST) activity
or through the action of glutathione peroxidase (GPx), which reduces hydrogen peroxide
while GSH is co-oxidized to its disulfide form (GSSG)[1, 2, 7, 8]. Additionally, GSH may
reversibly modulate cellular redox signaling via direct glutathionylation of thiol groups
within redox sensitive signaling proteins. This post-translational modification may also
protect thiol groups within redox sensitive signaling proteins from permanent modification
under oxidizing conditions[9, 10]. Similarly, GSH functions to protect mitochondrial 1-Cys
peroxiredoxins from damaging oxidation as the resolving thiol group in thioredoxin
catalyzed peroxidase activity in saccharomyces cerevisiae [11]. These functions and aspects
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of GSH homeostasis demonstrate the importance of the GSH/GSSG redox pair in the
maintenance of the cellular redox state.

Author Manuscript

The cellular redox state is commonly characterized by examining the ratio of reduced to
oxidized species within cellular redox pairs. High intracellular concentrations and redox
buffer capacity makes this especially true of the GSH/GSSG redox couple[1, 12–14].
Biochemically, GSH and GSSG may be thought of as components of an electrochemical
half-cell in which the flux of single electron transfers can be quantified by their electrical
potential or electromotive force, characterizing the proclivity of the GSH/GSSG pair to
donate or accept electrons in varying redox states. As a result, defining the individual
absolute cellular concentrations of GSH and GSSG and applying these concentrations, along
with measured values for intracellular pH (pHi) and cellular volume to the Nernst equation
allows for a more specific analysis of the 2GSH/GSSG redox state, the electrical half-cell
reduction potential (Ehc)[12, 13]. Although living biological systems never rest at a state of
equilibrium, characterization of the 2GSH/GSSG reduction potential provides a practical
snapshot of cellular redox balance[12, 15]. Furthermore, evaluation of the 2GSH/GSSG Ehc
is a strong indicator of the existing redox state of thiol-containing signaling proteins
regulated by glutathione.

Author Manuscript

The cellular GSH/GSSG ratio is characterized by the equilibrium half-cell reaction of
glutathione species resulting in the synthesis of two moles of GSH from the reduction of one
mole of GSSG, thus the glutathione based redox state is dependent on cellular GSH
concentrations[12, 13]. Alternatively, the individual concentrations of GSH and GSSG may
be considered when characterizing small dynamic changes in the cellular redox state over
time. Consequently, an effective evaluation of the glutathione based redox state requires a
sensitive and accurate method for the quantitation of absolute concentrations for both GSH
and GSSG. This is particularly important for evaluation of the cellular redox state within
hematopoietic malignancies manifesting in hematopoietic stem-progenitor cells (HSC/
MPPs); a tissue that has inherently limited availability for study in vivo. For example, in our
experience, purification of murine bone marrow typically results in the isolation of
approximately 20,000 HSC/MPPs from a single animal that demonstrate the Lin−, Sca-1+, ckit+ (LSK) phenotype.

Author Manuscript

HSC/MPP location and function require cellular quiescence and protection from oxidative
insult[16–18]. Thus, antioxidant defense is vital to stem cell function. This concept is
demonstrated by the increase in stem cell function resulting from treatment with the antioxidant and GSH precursor N-acetylcystiene (NAC)[19]. This is further demonstrated by the
major cellular regulator of transcriptional anti-oxidant signaling Nrf2; wherein, Nrf2−/ −
mice are characterized by an increase in HSC/MPP differentiation and a decrease in stem
cell function, indicating that a loss of cellular antioxidant machinery is detrimental to the
maintenance of HSC/MPP pools in vivo[20]. These observations indicate a potential role for
glutathione metabolism and maintenance in the regulation of redox balance and the resulting
effect on differentiation and self-renewal, within normal and malignant HSC/MPPs.
It is well recognized that regulation of glutathione metabolism is significantly affected by
the expression and activity of the ABC transporter ABCC1/MRP1 (multi-drug resistance
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protein 1)[21–24]. MRP1 demonstrates general ubiquitous tissue expression with the
exception of the liver hepatocyte, functioning to efflux GSH, GSSG, and glutathione
adducted metabolites with a km in the low mM range for GSH and nM to μM range for GSX adducted metabolites[21–26]. While the role of MRP1 in metabolism within peripheral
and specialized tissues has been well documented, the function of MRP1 and its effect on
glutathione concentrations as well as the HSC/MPP redox state within primitive HSC’s is
less understood. This is partially due to the inherently limited availability of lineage
primitive hematopoietic tissues, which display low glutathione concentrations in vivo, and is
compounded by the lack of sensitive methodologies capable of discerning small dynamic
changes in glutathione concentrations within these specialized hematopoietic populations.
However, the ability to accurately quantitate cellular GSH pools within these rare tissues is
needed because aberrant GSH metabolism may lead to an alteration of the HSC/MPP redox
state. These changes in HSC/MPP redox balance are closely associated with genetic
instability as well as proliferation, differentiation, and mobility within the HSC/MPP
populations in which hematopoietic disorders are thought to initiate and reside[18, 27–29].
As such, examining the GSH/GSSG based HSC/MPP redox state may provide insight to the
role of MRP1 and the glutathione redox pair in the onset and progression of hematopoietic
neoplasms. Additionally, many cancer therapies, including radiation and chemotherapeutics,
such as the anthracyclines, are known to exert a portion of their tumor killing effect through
the production of ROS, which may be remediated by adduction of GSH and efflux via
MRP1 further altering the malignant cell redox state. Together, these facets indicate that
accurate measurement of GSH/GSSG will aid interpretation of MRP1 function in HSC/
MPPs and how alterations in the cellular redox state may affect hematopoietic disease onset,
progression, and treatment.

Author Manuscript
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Many current methodologies utilized for GSH and GSSG quantitation are based on free thiol
conjugation followed by the observation of a fluorescent product, enzymatic reduction of
glutathione disulfide pools, and the chemical derivation of parent glutathione molecules
allowing for chromatographic separation[30–34]. These methodologies require complicated
chemical reactions, which may not reach completion, and large amounts of sample tissue.
Moreover, some methodologies may only accurately measure total glutathione content and
are not effective or ideal for accurately quantitating GSH/GSSG in small cell populations in
vivo, such as HSC/MPP’s. However, emerging methods which combine high performance
liquid chromatography with single or tandem mass spectrometry (LC-MS, LC-MS/MS) with
and without post column sample modification have quantitated GSH/GSSG in physiological
fluids[35, 36]. While these methods demonstrate the potential power of LC-MS/MS
analysis, they do so within an effectively unlimited sample population. Here we describe the
development and validation of a simple tissue extraction combined with a robust and
sensitive LC-MS/MS method, demonstrating high throughput potential, for the direct and
simultaneous quantitation of oxidized and reduced forms of glutathione in small HSC/MPP
populations. The application of this methodology is demonstrated in cell culture systems as
well as mouse bone marrow, including purified Lin−, c-kit+, Sca-1+ (LSK) populations.
Validation procedures performed were based on the recommended guidelines for LCMS/MS based analysis of small molecules in industry as set forth by the United States Food
and Drug Administration[37]. As a method and model control we examine cell populations
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demonstrating differential expression of MRP1 resulting in the characterization of MRP1
functional effect on glutathione concentrations within primitive HSC/MPP populations in
vivo. This control allows us to evaluate the ability of our LC-MS/MS method to detect fine
variations in glutathione concentrations with both in vitro and in vivo systems. We have
found that the over expression of MRP1 in MCF7 cells results in decreased intracellular
GSH/GSSG concentrations, while loss of Mrp1 expression in Mrp1−/− HSC/MPPs resulted
in the cellular accumulation of GSH and GSSG. These results indicate that MRP1
expression may have a direct impact on the cellular redox state of the HSC/MPP population.
Additional evaluation of the utility for this methodology is completed through the
quantitation of glutathione within cultured MDSL cells treated with chemotherapeutics
(Doxorubicin and Lenalidomide) that have been previously used for the treatment of
hematopoietic disorders such as acute myeloid leukemia (AML) or myelodysplastic
syndromes (MDS). Furthermore, we characterize glutathione concentrations in normal
human bone marrow as well as mononuclear cells isolated form patients afflicted with acute
myeloid leukemia. We found that acute myeloid leukemic cells derived from human bone
marrow demonstrate elevated levels of GSH, indicating a potential mechanism by which
leukemic stem cells balance elevated levels of oxidative stress produced during proliferation.

Author Manuscript

LC-MS/MS Materials
γ-L-Glutamyl-L-Cysteinyl-Glycine (GSH), γ-glutamyl-L-cyteinyl-glycine disulfide
(GSSG), ethylenediaminetetraacetic acid (EDTA), were purchased from Sigma-Aldrich (St.
Louis, MO). Trichloroacetic acid purchased from J. T. Baker (Center Valley, PA).
Chromatographic columns were purchased from Phenomenex (Torrance, CA). HPLC grade
solvents were purchased from Fisher Scientific (Pittsburgh, PA). Formic acid and
ammonium formate were purchased from Acros Organic (Pittsburgh, PA).

Author Manuscript

Cell Culture
MDSL cells were cultured in IMDM media (ATCC; Manassas, VA) supplemented with 20%
FBS (GE Healthcare; Pittsburgh, PA), 1% penicillin/streptomycin (Life Technologies; Grand
Island, NY), and 15 ng/mL recombinant human IL-3 (Peprotech; Rocky Hill, NJ). MDSL
cells were cultured at both 5% and 21% O2, 5% CO2, at 37° C. MCF7 cells were cultured in
DMEM media (Life Technologies; Grand Island, NY) supplemented with 10% FBS and 1%
penicillin/streptomycin in 5% CO2 at 37°C. MRP1 overexpressing MCF7 (MRP1-10, a gift
from Dr. Charles Morrow, National Institute of Health, Bethesda, Washington DC) cells
were cultured in DMEM media supplemented with 10% FBS and 1% penicillin/
streptomycin, 1.0 mg/mL G418, in 5% CO2 at 37°C.

Author Manuscript

LC-MS/MS Methodology
Mass spectrometric analysis was performed on a TSQ Vantage triple quadrupole mass
spectrometer (Thermo Fisher Scientific, Waltham MA) coupled with an ion max
electrospray ionization source containing a HESI II probe operated in positive ion mode.
The GSH/GSSG MS/MS method development was accomplish by direct infusion of a GSH/
GSSG standard (10 μg/mL) into the mass spectrometer at a flow rate of 5 μL/min. Single
reaction monitoring (SRM) was used to simultaneously analyze samples for GSH and
GSSG. The SRM’s for GSH (m/z 308.022 → m/z 84.056 + 162.002) and GSSG (m/z
Free Radic Biol Med. Author manuscript; available in PMC 2017 August 01.
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613.99 → m/z 231.034 + 354.993) were completed with collision energies and S-lens
voltages optimized for each individual transition. Other MS/MS method settings follow: Q1
and Q3 resolution at 0.7 FWHM, scan width at 0.1 amu, scan rate at 0.1 seconds, and
collision gas pressure at 1.0 mTorr. Tune parameters were as follows: spray voltage at 2700
V, vaporizer temperature at 200° C, capillary temperature at 250° C, sheath and auxiliary gas
pressures at 35 and 10 arbitrary units respectively. Liquid chromatography was performed on
a Shimadzu LC system containing a CMB-2A controller, a SIL-2A auto sampler, and two
LC-20 AD pumps (Canby, OR). Liquid chromatographic separation of 10 μL sample
injections were achieved on a Phenomenex Luna PFP(2) analytical column (100 mm x 2.0
mm, 3 μm) and completed under isocratic conditions, 99% mobile phase A (H2O, 0.75mM
ammonium formate, 0.01% formic acid), 1% solvent B (methanol) at 250 μL/minute over an
11 minute total run time.

Author Manuscript

Calibration Standards and Quality Control’s

Author Manuscript

Stock solutions of GSH and GSSG were prepared at 1 mg/mL by dissolving 1.0 mg of pure
powder stock in 1.0 mL of 2% TCA (1mM EDTA). One hundred μL aliquots were then
frozen at −80° C for no more than 7 days. Working stock solutions were created by 1:10
serial dilutions of the 1.0 mg/mL stock solutions in 2% TCA (1mM EDTA). A working
GSH/GSSG stock solution was mixed at 10 μg/mL and subsequently used to dilute working
standard concentrations of 500.0, 250.0, 100.0, 50.0, 25.0, 10.0, 7.5, 5.0, 2.5, 1.0, 0.5 ng/mL
for simultaneous GSH/GSSG standardization of the LC-MS/MS system. QC solutions of
5.0, 25.0, and 250.0 ng/mL (five injections at each concentration) were also diluted from the
10 μg/mL working GSH/GSSG stock solution. Standard curves and QC’s were prepared and
run on each day of analysis. Data acquisition and sample peak integration analysis was
completed with Xcalibur software, version 2.1 (Thermo Fisher). Standard, QC, and sample
concentrations were calculated with sample peak areas and linear equations (form y = mx +
b) generated by external standard curves for both GSH and GSSG.
Sample Extraction Methodology

Author Manuscript

Samples, prepared as described below were pelleted in a 5 mL round bottom tube by
centrifugation in a swinging bucket rotor at 1300 rpm for five minutes. Supernatants were
carefully discarded by vacuum aspiration. Cells were then re-suspended in 75 μL of
extraction buffer (2% TCA; 1.0 mM EDTA) and incubated on ice for 15 minutes after which
samples were vortexed for 45 seconds and incubated on ice for a further 15 minutes. Sample
pH was adjusted to 2.0 by mixing 50 μL of sample lysate with 50 μL of Mobile phase A
(HPLC grade H2O, 0.75 mM ammonium formate, 0.01% formic acid, pH=3.0) and cellular
debris was subsequently pelleted by centrifugation at 4,000 x g for 10 minutes. Supernatants
were collected for LC-MS/MS analysis.
Method Validation
The linear range of detection for both GSH and GSSG was determined and validated by the
analysis of the standard curve and QC samples generated as described above (n=3). A linear
regression was used to determine the correlation coefficient (r2 value) after plotting the
analyte peak area over the standard concentration. The inter-day slope precision was
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). Analyte stability at
expressed as the percent of the coefficient of variance (
various temperatures was determined by repeat analysis at the lowest QC concentration
(n=5) and is presented as percent of the concentration originally measured. Inter and intraday precision was determined by repeat standard and QC evaluation at three different
concentrations within the determined linear range in replicates of five (n=3). Again,
precision is presented as %CV. The lower limit of detection (LLOD) was determined by the
lowest peak height that generated a signal to noise ratio (S/N) greater than or equal to three
(S/N ≥ 3) for both GSH and GSSG. The lower limit of quantitation (LLOQ) for both analyte
species was identified as the minimum analyte concentration required to generate a signal to
noise ratio greater than or equal to five (S/N ≥ 5) as determined by standard addition
analysis described below.

Author Manuscript
Author Manuscript
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Because GSH and GSSG are produced endogenously, the cellular lysates produced during
sample extraction serve as the biological matrix. Thus, precision, accuracy and percent
recovery were evaluated by standard addition of known analyte concentrations to whole cell
lysates which were extracted at 30,000 cells per aliquot of lysate. Mouse whole bone
marrow was used for cross validation. Here, individual lysates of 30,000 cells/sample were
spiked with known amounts of standard GSH/GSSG solution. To accomplish standard
addition of MDSL cell lysates, 1.2 million MDSL cells were lysed in 3.0 mL of extraction
buffer (30,000 cells/ 75 μL of extraction buffer). Then, 75 μL of lysate was added to 75 μL
of blank extraction buffer or extraction buffer containing four times the target analyte (GSH/
GSSG) concentration and samples were then incubated on ice for 30 minutes. After
incubation, sample pH was adjusted to 2.0 by mixing 50 μL of sample containing the blank
lysate, +/− standard with 50 μL of mobile phase A. Samples were then spun down as
previously described and analyzed via LC-MS/MS. Standard addition of mouse whole bone
marrow was completed by preparing individual aliquots of 30,000 cells to which 75 μL of
either blank extraction buffer or extraction buffer containing two times the target analyte
concentration of GSH/GSSG was added. Samples were then incubated on ice for 15 minutes
after which the samples were vortexed for 45 seconds each, followed by another 15 minute
incubation period on ice. Cellular debris was then pelleted by centrifugation at 4,000 x g,
and the supernatants were collected for LC-MS/MS analysis. Standard addition for both cell
types was completed at 4 concentrations; 0.0, 5.0, 50.0, 250.0 ng/mL for GSH and 0.0, 1.0,
5.0, 50.0 ng/mL for GSSG. Each standard addition concentration was evaluated in replicates
of n=5. Target analyte concentrations were evaluated by subtracting the basal GSH/GSSG
concentrations obtained by LC-MS/MS analysis of the blank samples from the GSH/GSSG
concentrations calculated from the standard addition samples. Precision values at each
standard addition concentration are expressed as % CV, described above. Accuracy values
are expressed as % bias, which is taken as the percent deviation of the determined
experimental concentration from the proposed theoretical concentration
(

). The percent recovery values were determined as the

[

].

GSH/GSSG Analysis of Cultured Cells
MRP1 protein expression in MCF7 WT and MRP1 overexpressing MCF7 (MRP1-10) cells
was evaluated by flowcytometry analysis after incubation with a FITC conjugated antibody
Free Radic Biol Med. Author manuscript; available in PMC 2017 August 01.
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targeted to the first nucleotide binding domain (amino acids 617-932) of human ABCC1/
MRP1. MCF7 and MRP1-overexpressing MCF7 (MRP1-10) cells were plated at 100,000
cells per well in 12 well plates and were subsequently incubated in 5% CO2 at 37° C for 24
hours to allow for cellular attachment. Cells were then mechanically harvested, counted by
hemocytometer and 50,000 cells per sample were aliquoted into 500 μL of PBS (pH=7.0 for
LC-MS/MS analysis of GSH/GSSG as described above. Similarly, prior to analysis, MDSL
cells were plated at 200,000 cells/mL in a 24 well plate and were then incubated in 5% or
21% O2, 5% CO2, at 37° C for 24 hours. Cells were then counted by hemocytometer and
samples were diluted in 500 μL of PBS (pH=7.0) prior to LC-MS/MS analysis of GSH/
GSSG. Total GSH and GSSG concentrations (ng/mL) were converted to ng/sample by
multiplying by total sample volume, sample concentrations were then divided by the total
number of cells extracted, normalized to 20,000 cells per sample and reported as [GSH] and
[GSSG] in ng/20,000 cells.

Author Manuscript

LSK Purification by FACS Analysis
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Femurs and tibias were harvested from wild type (WT) and Mrp1 knock out (KO) mice of
the C57BL/6 background. Subsequently, bone marrow was aspirated with FACS buffer
(PBS, 2% HI-FBS pH=7.4) using a 2 mL syringe and a 27.5 gauge needle (BD biosciences,
San Jose, CA). Whole bone marrow was then pelleted by centrifugation at 1600 rpm for 3
minutes and the supernatant was discarded. Cells were then washed twice with FACS buffer.
Whole bone marrow was then re-suspended in red blood cell lysis buffer (150 mM NH4Cl,
10mM NaHCO3, 1 mM EDTA), filtered through a 5 mL (12 x 75 mm) polystyrene roundbottom tube with a cell strainer cap (BD Falcon, San Diego, CA) and incubated on ice for 5
minutes. Cells were then spun down at 1600 rpm for 3 minutes and the supernatant was
discarded. Cells were then washed twice with FACS buffer and re-suspended in 100 μL of
FACS buffer. After re-suspension cells were incubated with 2 μL (1:50 ratio) of conjugated
antibody corresponding to cell surface markers used for sorting Lin−, Sca-1+, c-kit+
hematopoietic stem cells (LSKs) on ice for 60 minutes. The antibodies used for sorting
LSK’s were as follows: Sca-1, Ly-6A/E-PE-Cy7; c-kit, CD-117-PerCP-Cy5.5; Lineage,
Cd45R-APC-Cy7, Cd3e-APC-Cy7, Ter199-APC-Cy7, Cd19-APC-Cy7, and Cd11b-APCCy7 (all Abs listed are raised in rat, anti-mouse and were purchased at 0.2 mg/mL from BD
Pharmigen, San Diego, CA). Subsequent to incubation, cells were washed and then resuspended in 500 μL of FACS buffer for fluorescence assisted cell sorting of LSKs at the
University of Kentucky flow cytometry facility. There, Lin−, Sca-1+, c-kit+ HSC/MPP’s
form both WT and Mrp1 KO mice were sorted such that LSKs from two mice were pooled
as one animal for GSH/GSSG analysis. Thus, six mice of each genotype were sorted as three
separate animals. LSKs were then taken directly to the University of Kentucky proteomics
core for analysis of absolute GSH/GSSG concentrations via LC-MS/MS.
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Cell Viability
MDSL cells were plated at a density of 200,000 cells/mL in complete MDSL cell medium
containing either vehicle or drug (10 μM Lenalidomide, Cayman Chemical, Ann Arbor MI;
or 25 nM Doxorubicin, Pfizer, New York, NY) in a 24 well plate and were incubated for 48
hours. Cells were then transferred to 5 mL round bottom tubes and washed twice with warm
HBSS (pH=7.4)(Gibco-Thermo Fischer, Waltham, MA). Cells were then re-suspended in
Free Radic Biol Med. Author manuscript; available in PMC 2017 August 01.
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MTT solution (0.5 mg/mL 3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide,
Sigma Aldridge St. Louis, MO; in RPMI media with no phenol red Gibco-Thermo Fischer,
Waltham, MA), aliquoted into a 96 well plate, and incubated at 37°C for 4 hours. Equal
volumes of lysis buffer (50/50, v/v, isopropanol/DMSO) were added to each well followed
by a 30 minute incubation at 37°C. Samples were then evaluated for absorbance at 560 and
690 nm using a Molecular Devices SpectraMax Plus 384 plate reader with SoftMax Pro
software.
Therapeutic Drug Treatments
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MDSL cells were plated at a density of 200,000 cells/mL in complete MDSL cell medium
containing either vehicle or drug (10 μM Lenalidomide, Cayman Chemical, Ann Arbor MI;
or 25 nM doxorubicin, Pfizer, New York, NY) in a 24 well plate and were incubated for 6
hours. Samples were then transferred to 5 mL round bottom centrifuge tubes, extracted, and
GSH/GSSG concentrations were analyzed via LC-MS/MS as previously described.
Patient Sample Collection and Analysis
Peripheral blood and bone marrow samples were obtained by Dr. Diana Howard, from the
Markey Cancer Center after individuals gave informed consent for tissue donation. White
blood cells were isolated by ficol gradient centrifugation as follows; patient tissue (21 mL of
blood or bone marrow) was diluted to 50 mL with phosphate buffered saline (sigma
Aldridge). Samples were then layered over 13 mL of Histopaque (Sigma Aldridge) and
centrifuged at 1400 rpm for 45 minutes. The white blood cell layer was then carefully
removed, diluted in freezing media (IMDM, 10% FBS, 1% penicillin/streptomycin, 10%
DMSO) and stored in liquid nitrogen (−180° C) until the time of LC-MS/MS analysis as
described above.
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Results
LC-MS/MS Method Development and Validation
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Past liquid chromatographic separation of glutathione has been accomplished with common
reverse phase C18 columns. However, we have found that GSH retention on these analytical
columns is minimal. Recently, Squellerio et al., described utilization of the Luna PFP-2
reverse phase column (Phenomenex) for the efficient retention of both glutathione species in
the LC-MS/MS analysis of GSH and GSSG from human whole blood samples. In agreement
with their findings, we found the Luna PFP-2 column to the optimal tool for
chromatographic retention and separation of the oxidized and reduced glutathione species.
While previous mass spectrometric based methodologies for the analysis of GSH/GSSG in
physiological fluids have been characterized, these methods are applied to the analysis of
samples for which there effectively is a nearly unlimited supply[35, 36]. To our knowledge,
none have examined the limits of sensitivity and potential for analysis of fine changes in
GSH/GSSG concentrations within rare and limited tissue populations, such as hematopoietic
stem cells in vivo.
To determine the quantitative limit for tissue sample analysis of GSH/GSSG concentrations
in vitro and demonstrate the effectiveness and sensitivity of these analytical parameters in
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vivo, we developed a modified LC-MS/MS method for direct and simultaneous GSH/GSSG
quantitation. The product ion spectra obtained were evaluated by the comparison to product
ion spectra acquired from the direct infusion of pure GSH/GSSG standard (figure 1A). The
chromatographic resolution of GSH and GSSG was confirmed by the collection and
evaluation of full product ion spectra resulting from the analysis of GSH and GSSG from a
biological sample (figure 1B). Upon completion of the LC-MS/MS SRM method
development, the average retention times for GSH and GSSG elution from the Luna-PFP2
reverse phase column, calculated from QC analysis were 2.69 +/− 0.02 and 4.37 +/− 0.03
minutes respectively (mean +/− SD, n=15). A typical extracted ion chromatogram obtained
from LC-MS/MS analysis of a 25 ng/mL standard is shown in Figure 2. Figure 3
demonstrates the typical results obtained from GSH/GSSG standard curve analysis.
Although separate external GSH and GSSG standard curves are generated, standard data
acquisition occurred simultaneously.

Author Manuscript

The method validation summary (Table 1) includes all parameters for LC-MS/MS method
validation as recommended by the USFDA[37]. The lower limit of detection for both GSH
and GSSG was 0.5 ng/mL as demonstrated by chromatographic peaks that have a signal to
noise ratio greater than 3. Precision, lower limits of quantitation (LLOQ) as determined by
accuracy measurements at various QC concentrations, and analyte recovery were all
determined by standard addition analysis. The lower limits of analyte quantitation were 5.0
ng/mL for GSH and 1.0 ng/mL for GSSG.

Author Manuscript
Author Manuscript

The USFDA recommends that accuracy values, which are defined as the closeness of a
concentration value obtained by the analytical method to the actual concentration value, and
precision values, defined as the closeness of individual measures of an analyte when the
procedure is applied to multiple aliquots of a single homogenous solution of biological
matrix, must be evaluated at three different concentrations within the analyte’s linear range
and must have five repeat evaluations at each concentration. These analyte evaluations must
have mean coefficient of variance values within 15% at medium and high concentrations
within the analyte’s linear range, and 20% at the LLOQ[37]. Table 1 summarizes the results
of this LC-MS/MS method validation. Analyte stability was evaluated at the lowest QC
concentration (5 ng/mL) for storage at 3 different temperatures. Our results agree with those
previously reported, demonstrating good GSH/GSSG stability within 15%, at +4° C and
−80° C. However, GSH stability, at the LLOQ, was slightly diminished (−23%) at room
temperature after a period of 24 hours. Slope and inter/intra-day precision values had
coefficient of variance values less than 10% (Table 1). A full method validation was
completed in MDSL cell lysates in which the accuracy values were all within 20% at the
LLOQ (GSH, 17.4%; GSSG, −1.6%) and medium to high concentrations demonstrated CV
values of less than 5% (Table 1). Precision %CV values were less than 15% at all
concentrations for both GSH and GSSG. Analyte recovery values, evaluated by standard
addition, were all within 10% of full analyte recovery for both GSH and GSSG. Finally, a
method cross validation by evaluation of accuracy and precision via standard addition was
completed in the mouse whole bone marrow biological matrix. Accuracy and precision
coefficient of variance values were determined to be within 15% at all concentrations for
both GSH and GSSG.
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To test the potential for this method to evaluate varying glutathione levels in biological
systems, we utilized a system with altered expression of Multidrug Resistance-associated
Protein 1 (ABCC1/MRP1). We first measured GSH/GSSG levels in MCF7 wild type cells,
known to not express MRP1, and compared these results to the GSH/GSSG measurement
within MCF7 cells overexpressing MRP1 (MRP1-10 cells). Differential MRP1 expression
levels within the two MCF7 cell lines was confirmed by flow cytometometric analysis of
FITC conjugated antibody directed to the first nucleotide binding domain of human
MRP1(data not shown). Figure 4 shows that overexpression of MRP1 resulted in a
significant decrease in cellular GSH and GSSG concentrations, −0.50 ng/20k cells for GSH,
and −0.13 ng/20k cells for GSSG (p=0.001), and that these changes lead to a significant
increase in the GSH/GSSG ratio, +8.42 (p=0.01, data not shown).
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This method was then used to evaluate GSH/GSSG concentrations in the absence of MRP1
in vivo. Both WT and Mrp1−/ − C57BL/6 mice were obtained and their hematopoietic stem
cells (Lin−, sca-1+, c-kit+; LSK’s) were isolated via fluoresce assisted cell sorting (Figure 5).
The typical yield for this isolation was approximately 20,000 cells from a single animal. The
results demonstrated that the LSK cells from Mrp1−/ − mice had a significant increase in
cellular GSH concentrations (+4.6 ng/20k cells, p=0.01). Interestingly, although differences
in the GSSG concentration were observed in LSK cells isolated from Mrp1−/ − and WT
mice, these changes were not judged to be statistically significant (Figure 6). These results
demonstrate the robustness and sensitivity of our LC-MS/MS methodology and its ability to
detect fine differences in GSH/GSSG concentrations within very limited tissue populations.
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Both the over expression and knock out of Mrp1 expression within various cell types
resulted in an increase of the GSH/GSSG ratio. This indicates that the evaluation of the
individual cellular concentrations of GSH and GSSG and not only their concentration ratio
is useful for an accurate interpretation of the GSH/GSSG based cellular redox state.

Author Manuscript

To further validate the utility of the methodology, MDSL cells were evaluated for GSH and
GSSG concentrations after treatment in vitro with two clinically relevant chemotherapeutic
agents, Doxorubicin (Adriamycin) and Lenalidomide (Revlimid). Traditionally, high risk
MDS patients presenting with blast crisis have been treated with high dose Cytarabine plus
an additional course of an anthracycline such as Doxorubicin. Because Doxorubicin is a
known ROS inducer, due its metabolic formation of an intermediate semi-quinone structure,
we compare the treatment effect and generation of ROS via doxorubicin to that of
Lenalidomide. Lenalidomide is known to act as an anti-inflammatory agent as well as a
stimulant of lymphocytes and erythropoiesis [38–41]. However, there is evidence that
suggests Lenalidomide can, itself, induce oxidative stress. This is observed in the use of
Lenalidomide for the treatment of a multiple myeloma model in which the combination of
Lenalidomide and the spin trap, ROS scavenger, phenyl-N-t-butylnitrone (PBN) effectively
modulates the transcriptional activation of AP-1 family transcription factors [42]. Recently,
Lenalidomide has been proven to be effective in the treatment of MDS mouse models and
has a significant cytotoxic effect in vitro, at 10 μM [43]. Doxorubicin (25 nM) and
Lenalidomide (10 μM) treatment of MDSL cells results in 21% (p=0.04) and 18% (p=0.02)
decreases in MDSL cell viability respectively (figure 7). Similar treatment effects are also
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demonstrated on cellular GSH and GSSG concentrations in vitro. A 6 hour treatment of
MDSL cells with Doxorubicin resulted in a 19% depletion of GSH (−5.72 ng/20k cells,
p=0.03) and a 15% (−0.019 ng/20k cells, p=0.03) depletion of GSSG compared to vehicle
control (figure 8). Similarly, 6 hour in vitro treatment of MDSL cells with Lenalidomide
resulted in a 10% (−2.09 ng/20k cells, p=0.01) depletion of GSH and a 15% (−0.013 ng/20k
cells, p=0.02) compared to vehicle controls (figure 8). Because the decreases in GSH and
GSSG upon treatment were very fine, there was no significant difference in the GSH/GSSG
ratio’s between treatment and control groups (data not shown). This again points to the
importance of individual species concentration determination rather than the examination of
the ratio between the reduced and oxidized forms of glutathione alone. Furthermore, the
elucidation of such minor, yet significant, changes in analyte concentration demonstrates the
sensitivity and robust nature of this methodology.
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Patient Sample Evaluation
Because cellular GSH/GSSG concentrations could play a significant role in disease onset
and progression, changes in cellular GSH/GSSG concentrations and the cellular redox state
may potentially serve as a biological marker for disease onset or severity. As such, we set
out to evaluate GSH/GSSG concentrations in ficol purified white blood cell populations
from patient samples donated by healthy individuals or those who had a confirmed case of a
hematopoietic malignancy. We measured GSH/GSSG concentrations in 5 samples collected
from healthy bone marrow (NBM), and 6 samples from patients diagnosed with acute
myeloid leukemia (AML). Figure 9 shows a significantly higher GSH levels in AML
compared to the NBM samples (+ 18.57 ng/mL), resulting in an increased GSH/GSSG ratio
(+2.87). This elevated GSH/GSSG redox state may compensate for the elevated oxidative
stress levels that malignant cells utilize for proliferation and disease progression.
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Discussion
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Recently, several mass spectrometric based methodologies have directly evaluated oxidized
and reduced glutathione extracted from physiological fluids. These methods have
demonstrated the ability to measure GSH/GSSG concentrations without the need for the
enzymatic reduction or chemical derivation of glutathione or glutathione disulfide prior to
endpoint detection[31, 33, 35, 36]. While effective, previous methods have been applied
only to large sample pools in which the limits of sample volume and method sensitivity are
not an issue. Following the USFDA Guidance for Industry on Bioanalytical LC-MS/MS
Method Validation, we have developed and described the validation of a sensitive and robust
LC-MS/MS method for the simultaneous and direct quantitation of the oxidized and reduced
forms of glutathione. We apply this methodology to the quantitation of GSH and GSSG at
the cellular level, and we use this method to determine the lower limit of tissue volume
required for accurate cellular GSH/GSSG quantitation. We have demonstrated the
quantitation of cellular GSH/GSSG within the murine stem cell populations and the
potential for GSH/GSSG analysis within HSCs derived from an individual animal. Our
analyses enable the determination of the physiologically relevant, functional effect of MRP1
expression on the glutathione based redox state within primitive HSC populations. Here, loss
of MRP1 expression results in an increase in cellular glutathione concentrations creating a
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more reducing intracellular environment. This result indicates that MRP1 may play an
important role in regulating redox balance within HSC’s and thus influencing the ability or
proclivity for HSCs to self-renew or differentiate into downstream functional populations.
Additionally, the ability to detect fine clinically relevant treatment induced variations in
glutathione concentrations within hematopoietic tissues, as demonstrated by the treatment of
MDSL cells with Doxorubicin and Lenalidomide, show that this methodology may be
capable of providing valuable insight to treatment toxicity as well as efficacy as it pertains to
the modulation of the cellular redox state in vivo.
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Because of the critical role of glutathione in cellular redox balance and signaling, we believe
that the tissue extraction and LC-MS/MS method described here will become an important
tool for examining how the cellular redox state may affect or be affected by the development
and treatment of hematopoietic neoplasms. Based on the data obtained from human samples,
we speculate that elevated redox stress within malignant hematopoietic cells may be
compensated with elevated levels of GSH and that the altered redox state may support
disease onset as well as drive disease progression[44]. The results suggest that there is a
potential for the future use of cellular GSH/GSSG concentrations as a bio-marker for
hematopoietic cancer; however, a much larger patient cohort must be evaluated.

Author Manuscript

GSH concentrations in the nucleus account for 10–15% of total cellular GSH, and 1–2% of
this total cellular GSH pool residing in the nucleus may be resistant to depletion by chemical
agents such as L-buthionine-[S,R]-sulfoximine (BSO)[45–49]. Thus, characterization of
nuclear GSH concentration and function can indicate GSH utility in nuclear protection from
oxidant insult, resulting in the faithful conservation of DNA replication and improved DNA
repair capabilities. Similarly, mitochondrial GSH may account for up to 30% of cellular
GSH[1, 8, 50, 51]. This mitochondrial pool of GSH protects other sulfhydryl containing
proteins and may partially regulate the function of ATPases, transporters, and
dehydrogenases by buffering the cellular redox status in the face of oxidative challenge[8].
Due to its sensitivity, our method may be utilized for the evaluation of GSH/GSSG
concentrations within separate subcellular fractions, such as nuclear extracts and purified
mitochondrial preparations. Future efforts to characterize subcellular GSH pools within rare
tissue populations may be accomplished by adopting this LC-MS/MS methodology into an
ultra-high pressure liquid chromatographic (UHPLC) system. The features of UHPLCMS/MS analysis result in tighter peak widths and greater peak heights resulting in improved
overall analyte sensitivity and higher throughput potential. Utilization and further
development of the methods we describe here can have an important impact on redox
biology research as it pertains to the development of hematopoietic malignancies in limited
and rare tissue populations as well as the impact of redox balance on subcellular function.
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•

LC-MS/MS method for the simultaneous analysis of oxidized and
reduced glutathione.

•

The method is validated based on FDA guidelines in vitro and in vivo
systems.

•

Detection of glutathione in rare HSPCs and drug induced variations of
GSH levels.

•

ABCC1 expression alters intracellular glutathione concentrations
within HSPCs.

•

Evaluation of glutathione as a potential biomarker for hematopoietic
malignancy.
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Figure 1.

A.) Both GSH (top) and GSSG (Bottom) were infused in line with a 50% solvent A, 50%
solvent B LC flow (200 μL/min) at a rate of 5 μL/min and at concentrations of 10μg/mL.
The resulting product ion spectra were obtained from GSH and GSSG parent ions. B.) The
chromatograms and spectra above resulted from the injection of a cellular extract isolated
from mouse LSK cells. The spectra below each chromatogram display the product ion
spectrum for the highlighted chromatographic peak above. Comparison of these spectra with
the infusion spectra (A) shown above confirm the presence of GSH and GSSG.
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Figure 2.

The chromatograph above demonstrates the simultaneous separation of reduced (GSH,
middle) and oxidized (GSSG, bottom) forms of glutathione. This injection sample consisted
of 10 μl of a 25 ng/mL QC sample (0.25 ng on column) routinely run during instrument
standardization.
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The linear plots above are examples of typical standard curves for both GSH and GSSG.
Although separate curves are generated, GSH and GSSG standardization of the LC-MS/MS
system takes place simultaneously. 1 mg/mL standards for GSH and GSSG are prepared in
1% TCA (1.0 mM EDTA, 50% solvent A). These standards are then mixed at 10 μg/mL
each and are subsequently diluted down in a stepwise fashion with 1%TCA (1.0 mM EDTA,
50% solvent A) to create the working solutions of standard and QC concentrations displayed
in the linear range above. Fresh standards and QC’s are prepared the day sample analysis
takes place.
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Figure 4.

Mean GSH/GSSG concentrations were evaluated in MCF7 WT and MCF7 cells
overexpressing MRP1 (MRP1-10). Significant differences in GSH concentration between
MCF7 (1.37 ng/20k cells) and MRP1-10 cells (0.87 ng/20k cells) were determined
(p=0.001). Additionally, significant differences in GSSG concentration between MCF7 (0.19
ng/20k cells) and MRP1-10 cells (0.06 ng/20k cells) were determined (p=0.001). These
changes resulted in a significant alteration to the GSH/GSSG ratio between the two cell lines
7.4 (MCF7) vs 15.82 (MRP1-10) (p=0.01).
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Figure 5.

Fluorescence Assisted Cell Sorting (FACS) purification of Lin−, Sca-1+, c-kit+ (LSK)
hematopoietic stem cells (HSC’s). Bone marrow from C57BL6 wild type (WT, Bottom) and
Mrp1 knock out (KO, Top) mice used for GSH/GSSG analysis. This analysis routinely
resulted in the purification of approximately 20,000 cells per mouse.
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Figure 6.

The concentrations of GSH, GSSG and their cellular ratio determined in WT and Mrp1 KO
mouse LSK cells purified as described earlier. The graph depicts the differences in analyte
concentrations between genotypes. A significant difference in mean GSH concentration is
demonstrated between the Mrp1 KO (5.64 ng/20k cells) and WT (1.04 ng/20k cells) animals
(p=0.01). A difference in the GSSG concentration between genotypes was found (KO, 1.07
ng/20k cells vs WT, 0.17 ng/20k cells) but this difference was not statistically significant.
Similarly no significant difference in GSH/GSSG ratios was determined (KO, 8.56 vs WT,
6.16).
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Figure 7.

MDSL cell viability was evaluated via MTT assay after 48 hour treatment with 25 nM
Doxorubicin and 10 μM Lenalidomide in vitro. Both treatments resulted in a significant
decrease of cell survival, 21% for Doxorubicin (p=0.04) and 18% for Lenalidomide
(p=0.02). Results are expressed as percent cell survival normalized to the vehicle control.
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Figure 8.

MDSL cell GSH (A) and GSSG (B) concentrations were analyzed after 6 hour drug
treatment in vitro. Both Doxorubicin (25 nM) and Lenalidomide (10 μM) caused significant
depletion of GSH and GSSG (Dox GSH −5.72 ng/ 20k cells, p=0.03; Dox GSSG −0.019
ng/20k cells, p=0.03; Len GSH −2.09 ng/20k cells, p=0.02; Len GSSG −0.013 ng/20k cells
p=0.01).
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Figure 9.

Mean GSH, GSSG concentrations and their cellular concentration ratio analyzed within
lymphocytes purified from the peripheral blood of AML patients as was the bone marrow
obtained from normal patient donors. LC-MS/MS analysis revealed a significant increase in
GSH concentrations within the AML (28.15 ng/mL) vs NBM (9.58 ng/mL) sample
populations (p=0.03), resulting in a significant increase in the GSH/GSSG ratio, 3.94 in
AML vs 1.16 in NBM patients (p=0.04). No significant difference was determined in GSSG
concentrations between patient groups (AML, 8.77 ng/mL vs NBM, 7.73 ng/mL).
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The table above summarizes the results of the LC-MS/MS method validation for the simultaneous analysis of
reduced and oxidized forms of glutathione. The Lower Limit of Detection and Quantitation were taken as the
concentrations which exhibit a signal greater than or equal to that of three (LLOD) and five (LLOQ) times the
intensity of a blank matrix injection respectively. All standards and QC’s had an injection volume of 10 uL and
were analyzed using the LC-MS/MS method previously summarized. Inter-day standard and slope analysis
was completed over 3 days with a linear range of 0–500 ng/mL. QC’s levels evaluated were at 5, 25, and 250
ng/mL over 3 days for inter-day precision analysis. Intra-day precision analysis was completed with an n=5 for
each concentration on the same day.
Method Validation Summary
Stability (%)

GSH

GSSG

Author Manuscript

RT (24 hr)

77

91

+4 Deg C (24 hr)

111

94

−80 Deg C (7 Days)

91

95

LLOD (ng/mL)

0.5

0.5

LLOQ (ng/mL)

5.0

1.0

Inter-day St. Curve Slope Precision (%CV)

6.2

3.5

GSH 5 ng/mL; GSSG, 5 ng/mL

4.9

6.5

GSH 50 ng/mL; GSSG, 50 ng/mL

2.0

3.3

GSH 250 ng/mL; GSSG, 250 ng/mL

2.0

2.4

Intra-day QC Precision (% CV)

Inter-day QC Precision (%CV)

Author Manuscript

GSH 5 ng/mL; GSSG, 5 ng/mL

4.3

8.7

GSH 50 ng/mL; GSSG, 50 ng/mL

3.0

3.5

GSH 250 ng/mL; GSSG, 250 ng/mL

1.4

2.3

17.4 (5.87 ng/mL)

−1.6 (0.98 ng/mL)

Accuracy (Mean % Bias Relative to Theoretical Standard Concentration)
MDSL Cell Line
GSH 5 ng/mL; GSSG, 1 ng/mL
GSH 50 ng/mL; GSSG, 5 ng/

1.1 (50.55 ng/mL)

1.8 (5.09 ng/mL)

GSH 250 ng/mL; GSSG, 50 ng/mL

1.2 (253.06 ng/mL)

0.1 (50.94 ng/mL)

Mouse Whole Bone Marrow
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GSH 5 ng/mL; GSSG, 5 ng/mL

2.1 (5.10 ng/mL)

0.4 (5.07 ng/mL)

GSH 50 ng/mL; GSSG, 50 ng/mL

−9.7 (45.16 ng/mL)

0.2 (50.09 ng/mL)

GSH 250 ng/mL; GSSG, 250 ng/mL

−2.4 (243.95 ng/mL)

0.5 (251.28 ng/mL)

Precision (% CV)
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Stability (%)

GSH

GSSG

GSH 5 ng/mL; GSSG, 1 ng/mL

11.3

14.5

GSH 50 ng/mL; GSSG, 5 ng/mL

4.3

2.4

GSH 250 ng/mL; GSSG, 50 ng/mL

1.1

1.7

MDSL Cell Line

Mouse Whole Bone Marrow
GSH 5 ng/mL; GSSG, 5 ng/mL

13.2

5.1

GSH 50 ng/mL; GSSG, 50 ng/mL

7.6

1.9

GSH 250 ng/mL; GSSG, 250 ng/mL

5.0

2.1

Recovery (% Compared to Measured Blank Concentration)
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MDSL Cell Line
GSH 5 ng/mL; GSSG, 1 ng/mL

101.5

99.6

GSH 50 ng/mL; GSSG, 5 ng/mL

100.9

102.4

GSH 250 ng/mL; GSSG, 50 ng/mL

105.1

101.2
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